Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Study sponsor: Bolt Biotherapeutics, Inc. · BOLT
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-09-20Actual
Enrollment · participants11Actual
Source updated2025-11-20Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.